Abpro Corporation (ABP)
0.94
-0.02 (-2.08%)
At close: Feb 04, 2025, 3:59 PM
0.98
4.24%
After-hours Feb 04, 2025, 06:53 PM EST
undefined% (undefined)
| Bid | 0.98 |
| Market Cap | 48.71M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.32 |
| PE Ratio (ttm) | -2.94 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.29 |
| Volume | 66,787 |
| Avg. Volume (20D) | 750,835 |
| Open | 0.96 |
| Previous Close | 0.96 |
| Day's Range | 0.92 - 0.99 |
| 52-Week Range | 0.90 - 13.00 |
| Beta | undefined |
About ABP
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2022
Employees 15
Stock Exchange NASDAQ
Ticker Symbol ABP
Website https://abpro.com